Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Endocrine Exam 2 > Diabetes Lecture 2 - Jaber > Flashcards

Diabetes Lecture 2 - Jaber Flashcards

1
Q 
The follow up study to DCCT is called:
A. HOPE
B. ACCORD
C. EDIC
D. EPIC
A

C. EDIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Kumamoto study was the first study in type ___ diabetics.

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

UKPDS is the largest study in type __ diabetics, and examined micro vascular complications.

A

Type 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q 
Which of the following studies looked at 7% A1C reduction in the intensive group and 8% A1C in the conventional group?
A. DCCT
B. EDIC
C. Kumamoto
D. UKPDS
A

D. UKPDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

During the studies done on diabetic patients in reduction of hemoglobin A1C, it was shown that in the intensive groups, even though when they finished the studies their A1C was less controlled, it was shown that the reduction in microvascular and macrovascular complications were sustained. This is called the ____ effect.

A

Legacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q 
All of the following examined macrovascular complications EXCEPT:
A. ACCORD
B. DCCT
C. ADVANCE
D. VADT
A

B. DCCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q 
Which of the following studies was terminated early due to increased risk of mortality in intensive group?
A. ACCORD
B. DCCT
C. ADVANCE
D. VADT
A

A. ACCORD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The conclusions of multiple studies conducted were that lowering A1C to below or around __% reduces microvascular complications.

A

7%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Weight loss meds may be appropriate for select T2DM patients with BMI =/> 27. Orlistat is a weight loss medication with which MOA?
A. Lipase inhibitor
B. Selective serotonin receptor agonist
C. Sympathomimetic anorectic/antiepileptic combo
D. Opioid antagonist/antidepressant combo
E. Glucagon like peptide 1 agonist

A

A. Lipase inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Weight loss meds may be appropriate for select T2DM patients with BMI =/> 27. Liraglutide is a weight loss medication with which MOA?
A. Lipase inhibitor
B. Selective serotonin receptor agonist
C. Sympathomimetic anorectic/antiepileptic combo
D. Opioid antagonist/antidepressant combo
E. Glucagon like peptide 1 agonist

A

E. Glucagon like peptide 1 agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Weight loss meds may be appropriate for select T2DM patients with BMI =/> 27. Lorcaserin is a weight loss medication with which MOA?
A. Lipase inhibitor
B. Selective serotonin receptor agonist
C. Sympathomimetic anorectic/antiepileptic combo
D. Opioid antagonist/antidepressant combo
E. Glucagon like peptide 1 agonist

A

B. Selective serotonin receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Weight loss meds may be appropriate for select T2DM patients with BMI =/> 27. Naltrexone/bupropion is a weight loss medication with which MOA?
A. Lipase inhibitor
B. Selective serotonin receptor agonist
C. Sympathomimetic anorectic/antiepileptic combo
D. Opioid antagonist/antidepressant combo
E. Glucagon like peptide 1 agonist

A

D. Opioid antagonist/antidepressant combo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Weight loss meds may be appropriate for select T2DM patients with BMI =/> 27. Phentermine/Topiramate is a weight loss medication with which MOA?
A. Lipase inhibitor
B. Selective serotonin receptor agonist
C. Sympathomimetic anorectic/antiepileptic combo
D. Opioid antagonist/antidepressant combo
E. Glucagon like peptide 1 agonist

A

C. Sympathomimetic anorectic/antiepileptic combo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Orlistat, a weight loss medication used in T2DM, is associated with this/these adverse effect(s).
A. Teratogenic
B. Heart valve disorder and bradycardia
C. Pancreatitis and acute renal failure
D. Liver failure and oxalate nephropathy
E. Mania, depression, and physical dependence

A

D. Liver failure and oxalate nephropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Lorcaserin, a weight loss medication used in T2DM, is associated with this/these adverse effect(s).
A. Teratogenic
B. Serotonin syndrome, heart valve disorder, and bradycardia
C. Pancreatitis and acute renal failure
D. Liver failure and oxalate nephropathy
E. Mania, depression, and physical dependence

A

B. Serotonin syndrome, heart valve disorder, and bradycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phentermine/Topiramate, a weight loss medication used in T2DM, is associated with this/these adverse effect(s).
A. Teratogenic
B. Serotonin syndrome, heart valve disorder, and bradycardia
C. Pancreatitis and acute renal failure
D. Liver failure and oxalate nephropathy
E. Mania, depression, and physical dependence

A

A. Teratogenic

17
Q

Naltrexone/bupropion, a weight loss medication used in T2DM, is associated with this/these adverse effect(s).
A. Teratogenic
B. Serotonin syndrome, heart valve disorder, and bradycardia
C. Pancreatitis and acute renal failure
D. Liver failure and oxalate nephropathy
E. Mania, depression, and physical dependence

A

E. Mania, depression, and physical dependence

18
Q

Liraglutide, a weight loss medication used in T2DM, is associated with this/these adverse effect(s).
A. Teratogenic
B. Serotonin syndrome, heart valve disorder, and bradycardia
C. Pancreatitis and acute renal failure
D. Liver failure and oxalate nephropathy
E. Mania, depression, and physical dependence

A

C. Pancreatitis and acute renal failure

19
Q

True or False: if a patient’s response to weight loss meds is <5% after 1 month, then the medication should discontinued.

A

False. Medication should be discontinued if patient fails after 3 months.

20
Q

To be considered for bariatric surgery, a patient must have T2DM, conmorbidities that are difficult to control with lifestyle and pharmacological therapy, and a BMI =/> ____.

A

35

21
Q

The diabetes control and complication trial (DCCT) was done in type __ patients.

A

Type 1 diabetics

Endocrine Exam 2 (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions